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Klavuzons are 6-(naphthalen-1-yl) substituted 5,6-dihydro-2H-pyran-2-one derivatives showing promis-
ing antiproliferative activities in variety of cancer cell lines. In this work, racemic syntheses of nine novel
40-alkyl substituted klavuzon derivatives were completed in eight steps and anticancer properties of
these compounds were evaluated. It is found that size of the substituent has dramatic effect over the
potency and selectivity of the cytotoxic activity in cancerous and healthy pancreatic cell lines. The size
of the substituent can also effect the CRM1 inhibitory properties of klavuzon derivatives. Strong cytotoxic
activity and CRM1 inhibition can be observed only when a small substituent present at 40-position of
naphthalen-1-yl group. However, these substituents makes the molecule more cytotoxic in healthy pan-
creatic cells rather than cancerous pancreatic cells. Among the tested compounds 1,2,3,4-tetrahy-
drophenanthren-9-yl substituted lactone was the most cytotoxic compound and its antiproliferative
activity was also tested in 3D spheroids generated from HuH-7 cell lines.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Current the 5-year survival rates for lung and pancreatic can-
cers are 18% and 8%, respectively. These low survival rates are par-
tially because of the late diagnosis of one-half of cases, in which 5-
year survival decrease to 4% and 3%, respectively.1 Currently, FDA
has approved more than ten anticancer drugs for the treatment
of pancreatic cancer but poor survival rates indicates the urgency
of the development of novel anticancer drug candidates. In this
work, development of novel klavuzon derivatives, as new anti-
cancer drug candidates for the treatment of pancreatic cancer,
was studied.
In recent years, there is an increase in the number of studies for
the discovery of drug candidates, which act by covalent binding to
the nucleophilic sites of the macromolecules inside the cells.
Almost, 30% of drugs in use today act as covalent inhibitor.2 One
of the most common motif in the structure of natural products is
a,b-unsaturated-d-lactone that can act as an irreversible inhibitor
through a covalent bond formation. It is believed that, nucleophilicsite of the enzymes can bind to the b-carbon of the lactone phar-
macophore through by Michael addition.3
(R)-Goniothalamin (1) is one of these natural products and was
isolated first in 1967 by Hlubucek from Cryptocarya caloneura.4 Its
selective cytotoxic activity against cancer cell lines5,6 draw the
attention of scientist and many research groups have put effort
in synthesizing novel derivatives of goniothalamin to understand
the structure activity relationship.7–16 On the other hand, a few
number of studies were dedicated to explore the mechanism of
action of goniothalamin derivatives such as inhibition of CRM1
nucleocytoplasmic transport receptor protein17 and inhibition of
topoisomerase I.18 In terms of cell death, it was shown that (R)-
enantiomer of goniothalamin induces apoptosis while (S)-enan-
tiomer induces autophagy.19 Efficiency of racemic and enantiomer-
ically pure forms of goniothalamin was also demonstrated in
Ehrlich solid tumor in mice.20
Previously, synthesis and antiproliferative activity of conforma-
tionally constrained (R)-goniothalamin ((R)-2) was reported by our
group. Although it was found that antiproliferative activity of com-
pound (R)-2 was higher than that of (R)-goniothalamin (1), naph-
thalen-1-yl substitution at position-6 of 5,6-dihydro-2H-pyran-2-
one pharmacophore further increases the activity. The inventors
named this compound as ‘‘klavuzon”. In the same study, (R)-40-
Fig. 1. Structures of (R)-goniothalamin (1), conformationally constrained (R)-
goniothalamin (2), 40- and 20-substituted klavuzon derivatives (3–6).
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found to be the most cytotoxic compound.21 In a recent study,
racemic 40-methoxyklavuzon (5) and (R)-20-methoxyklavuzon (6)
derivatives were also prepared and they were found to be less
cytotoxic compared to their methyl counterparts ((R)-3 and (R)-
4). In the same study, topoisomerase I inhibitory property of klavu-
zon derivatives was also represented (Fig. 1).18
Multi-target drug discovery gained significant attention in the
last decade to overcome the difficulty of curing diseases having
complex etiology and drug-resistance issues.22 In this respect,
goniothalamin derivatives can be considered as a dual acting inhi-
bitor because of its capability to inhibit both CRM1 and topoiso-
merase I. Due to their structural similarity to goniothalamin,
klavuzons may also have similar dual acting inhibitor property.
Previously, topo I inhibitory property of klavuzons was shown. In
this study, synthesis and antiproliferative properties of novel 40-
alkyl substituted klavuzon derivatives in pancreatic cancer cells
(MIA PaCa-2) and Human pancreatic ductal epithelial cells
(HPDEC) will be presented. Their time and concentration depen-
dent CRM1 inhibitory properties will also be discussed.2. Results and discussion
Racemic syntheses of 40-alkylklavuzon derivatives (16a–h)
were completed in eight steps. Strategically important ethyl 4-
alkyl-1-naphthoates (10a–h) were prepared according to the pro-
cedures reported in literature starting from 4-methyl-1-naphthoic
acid (7) in three steps. As can be seen in Scheme 1, benzylic bromi-
nation of ethyl 4-methyl-1-naphthoate (8) was performed by a
NBS-benzoyl peroxide mixture to produce compound 9 in 92%
yield. In the next step, the copper (I)-catalyzed addition of various
freshly prepared Grignard reagents to 4-bromomethyl-1-naph-
thoate (9) was successfully performed.23 Interestingly, varying
amounts of dimerization product (11) of 4-bromomethyl-1-naph-
thoate (9) were also observed.
Ethyl 1-naphthoates (10a–h) were successfully reduced to 1-
naphthylmethanols (12a–h) by using LiAlH4 with 8–87% yields.
Then PCC was used to convert the alcohols into the corresponding
4-alkyl-1-naphthaldehyde derivatives (13a–h) with relatively
higher yields (58–90%) as represented in Scheme 2. Then, a well-
known three step synthesis was used to complete the syntheses.
Simply, addition of allylmagnesium bromide over 1-naphthaldehy-
des (13a–h) and commercially available 4-methyl-1-naphthalde-
hyde (13i) yielded homoallylic alcohols (14a–i) in 54–91% yields.Acrylation with acryloyl chloride in the presence of triethylamine
followed by ring closing metathesis reactions gave the final
klavuzon derivatives (3 and 16a–h, Scheme 2). Another important
klavuzon derivative 20 was also prepared by the same three step
synthesis starting from commercially available 1,2,3,4-tetrahy-
drophenanthrene-9-carbaldehyde (17) as represented in
Scheme 3.
Alternatively, 5,6-dihydro-2H-pyran-2-one pharmacophore can
be prepared from the isomerization of 3,6-dihydro-2H-pyran 2-one
in the presence of an amine base. A similar isomerization can also
be observed for naphthalen-1-yl substituted 3,6-dihydro-2H-pyran
2-one derivatives inside the cells to give the corresponding klavu-
zons, so derivatives of 3,6-dihydro-2H-pyran 2-one may have ther-
apeutic importance. For these reasons, a list of 4-alkylnaphthalen-
1-yl substituted 3,6-dihydro-2H-pyran 2-one derivatives (23a–e)
were also prepared starting from 4-methyl-1-naphthoic acid
(Scheme 4).
Compounds 13a–h were synthesized by the same synthetic
route reported above and then reacted with vinylmagnesium bro-
mide to give allylic alcohols 21a–e with 67–87% yields. Steglich
esterification of the formed alcohols with but-3-enoic acid gave
esters 22a–e. Finally, ring closing metathesis reactions of the esters
22a–e yielded 4-alkylnaphthalen-1-yl substituted 3,6-dihydro-2H-
pyran 2-one derivatives (23a–e).
Although, compounds 23a–e were isolated and characterized
successfully, it was noted that these compounds totally decom-
posed even at +4 C in three months. Decomposition of 6-(4-
methylnaphthalen-1-yl)-3,6-dihydro-2H-pyran 2-one (23a). was
also shown by 1H NMR spectroscopy in Fig. 2. Observed instability
of the 4-alkylnaphthalen-1-yl substituted 3,6-dihydro-2H-pyran 2-
one derivatives led us to convert compound 23b–e to the corre-
sponding klavuzon derivatives 16b–e by isomerization with DBU,
instead of testing them to determine their antiproliferative proper-
ties (Fig. 3).
Antiproliferative properties of all prepared klavuzon derivatives
(3, 16a–h and 20) were tested in healthy (HPDEC) and cancerous
(MIA PaCa-2) pancreatic cell lines by MTT cell viability assay.
Camptothecin (CPT) was used as positive control. There were dif-
ferences between the cell culture conditions of both cell lines,
and the most important difference was that HPDEC should be cul-
tured (and tested) over type I collagen coated surface. Because
there is a Michael acceptor in the structure of klavuzon, a small
amount of the tested compounds can bind to the collagen and
actual level of cytotoxicity may not be observed. To determine
the effect of the collagen in MTT assay, three klavuzon derivatives
(3, 16b and 16c) were also tested in MIA PaCa-2 cell lines which are
cultured in type I collagen coated 96 well microplate. All IC50 val-
ues calculated for klavuzon derivatives were summarized in
Table 1.
According to these data, collagen coating did not have any influ-
ence in structure activity relationship of klavuzon derivatives. It
slightly increased the IC50 values for compounds 3 and 16c. It
might be possible that MIA PaCa-2 cell viability and resistance to
goniothalamin increases in the presence of type I collagen or a
small amount of klavuzons was bound to the collagen as expected.
On the other hand, effect of collagen over the IC50 value of com-
pound 16b was more dramatic. It is difficult to announce the rea-
son for this difference between the IC50 values of compounds 16b
and 16c. In one thought, this difference may not be the result of
interactions between klavuzon and collagen because if that is the
case compounds 16b should have similar IC50 values for HPDEC
and MIA PaCa-2 cell lines cultured over collagen. Only explanation
can be the development of a resistance in MIA PaCa-2 cells when
they grow over collagen. Overall, it can be concluded that SAR of
klavuzon derivatives was not affected by collagen coating
(Table 1).
Scheme 1. Conversion of 4-methyl-1-naphthoic acid (7) into ethyl 4-alkyl-1-naphthoate derivatives (10a–h).
Scheme 2. Transformation of ethyl 4-alkyl-1-naphthoate derivatives (10a–h) to 40-alkyl substituted klavuzon derivatives (16a–h).
Scheme 3. Synthesis of 6-(1,2,3,4-tetrahydrophenanthren-9-yl)-5,6-dihydro-2H-
pyran-2-one (20).
Scheme 4. Synthesis of 4-alkylnaphthalen-1-yl substituted 3,6-dihydro-2H-pyran-
2-one derivatives (23a–e).
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sensitive to camptothecin (CPT), a well known topoisomerase I poi-
son. Interestingly, CPT does not show any selectivity over cancer
cell lines probably due to the duplication times for cancerous
(MIA PaCa-2) and immortalized healthy (HPDEC) cell lines were
quite close to each other (40 and 34 h, respectively). As it can be
seen in Table 1 compound 20 showed five and two times stronger
Fig. 2. Decomposition of 6-(4-methylnaphthalen-1-yl)-3,6-dihydro-2H-pyran 2-one (23a). (Spectra 1: freshly prepared; Spectra 2: after one month; Spectra 3: after three
months).
Fig. 3. Isomerization of 6-(4-alkylnaphthalen-1-yl)-3,6-dihydro-2H-pyran 2-one
derivatives.
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HPDEC cell lines, respectively. Level of cytotoxic activity of 40-
ethylklavuzon (16a) was stronger compared to 40-methylklavuzon
(3) in both cell lines, but selectivity was getting worse. In general,
presence of a linear alkyl chain at position 40- of klavuzon (3 and
16a–d) caused slightly selective cytotoxic activity for healthy pan-
creatic cell line (HPDEC). The length of the alkyl chain negatively
affected potency of these compounds and shorter alkyl chains
resulted more cytotoxic klavuzon derivatives. On the other hand,
presence of a more bulky group at 40- position gave klavuzon
derivatives (16e–h) that have comparable potency with 40-propyl
and 40-butyl substituted klavuzons (16b and 16c). Nevertheless,
selectivity index enhanced to 0.91–1.31 interval (Table 1).
Induction of apoptosis and cell cycle analysis of MIA PaCa-2
cells treated with varying concentrations of 40-methylklavuzon
(3) were also studied by using Annexin V-FITC apoptosis detectionTable 1
Antiproliferative effect of 40-alkyl substituted klavuzon derivatives (16a–i) over MIA PaCa
Comp. IC50 (in lM)
MIA PaCa-2
Collagen No coll
CPT 0.18 ± 0.01
3 0.96 ± 0.17 1.23 ± 0
16a 0.83 ± 0.12
16b 1.50 ± 0.61 2.62 ± 1
16c 6.30 ± 0.73 7.37 ± 1
16d 6.70 ± 0.20
16e 4.09 ± 0.20
16f 2.20 ± 0.11
16g 3.21 ± 0.39
16h 1.40 ± 0.69
20 0.16 ± 0.03
SI: Selectivity Index = IC50 in HPDEC/IC50 in MIA PaCa-2, where IC50 is the concentrationkit (Fig. 4). At the end of 24 h of incubation with compound 3 the
percentage of the early apoptotic MIA PaCa-2 cells slightly
increased by concentration dependent manner. A similar statisti-
cally significant amount of increase was observed for the percent-
age of the late apoptotic cells, while the percentage of the necrotic
cells did not change.
Besides, cell cycle analysis gave the clues about the existence of
more than one action of mechanism for 40-methylklavuzon (3).
Incubation with low dose (1 lM) of compound 3 resulted a small
increase at G1 phase while that causes a similar amount of
decrease at S phase. The number of cells at G1 phase decreased sig-
nificantly in MIA PaCa-2 cell line incubated with 5 and 10 lM of 40-
methylklavuzon for 24 h. Contrarily, number of cells at G2 phase
increased significantly at the same concentrations. There is a small
rise in the number of cells at S phase in the presence of 10 lM of 40-
methylklavuzon but this increment was not significant (Fig. 4). Cell
cycle arrest at S phase may be the indication of Topo I inhibitory
property of 40-methylklavuzon (3) and it is required high doses
of compound 3. In addition, cell cycle arrest at G2 phase could
mean that a number of cells complete the DNA duplication and
another mechanism blocks the cell division at this stage.
According to apoptosis and cell cycle analysis, compound 3
causes apoptosis or cell cycle arrest only in a small fraction of cell
population even at 10 lM concentration at the end of 24 h incuba-
tion period. However, IC50 value of compound 3 in MIA PaCa-2 cells
was calculated as 0.96 lM for 48 h treatment. There should be a
sign for this cytotoxic effect at 24 h incubation. To control DNA
integrity comet assay was performed for MIA PaCa-2 cells treated-2 pancreatic cancer cell line and HPDEC immortalized healthy pancreatic cell line.
SI
HPDEC
agen
0.21 ± 0.01 1.17
.34 0.34 ± 0.09 0.35
0.19 ± 0.05 0.23
.09 0.47 ± 0.15 0.31
.21 0.49 ± 0.17 0.08
2.83 ± 0.38 0.42
4.50 ± 0.48 1.10
2.88 ± 0.49 1.31
3.97 ± 0.50 1.24
1.28 ± 0.11 0.91
0.15 ± 0.04 0.94
required to decrease the cell population 50%. CPT: camptothecin.
Fig. 4. Concentration dependent apoptosis and cell cycle analysis for 40-methylklavuzon (3) treated MIA PaCa-2 cells.
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lysis solution was used to detect the possible double and single
strand DNA breaks.24 Hydrogen peroxide was used as positive con-
trol. Formation of DNA breaks could easily be seen for 53% MIA
PaCa-2 cells treated with 5 lM of 40-methylklavuzon (3), although
total number of the apoptotic cells was around 14% of the total cell
population. A similar inconsistency was also found for MIA PaCa-2
cells treated with 10 lM of compound 3. While only 20% of the
cells were apoptotic at this concentration, 42% of the cell popula-
tion gave comet as an indication of DNA breaks. Mismatch between
the percentages of cells at apoptosis and percentages of cells giving
comet can be explained by Topo I inhibition property of klavuzons.
Topoisomerases, including topoisomerase I, play crucial role in the
cellular response to DNA damage, DNA repair and apoptosis.25 AnyFig. 5. Comet assay for MIA PaCa-2 cells treated with 40-methylklavuzon (3).damage in DNA cannot be repaired when all Topo I enzymes are
inhibited by compound 3.
Nucleocytoplasmic transport systems play a critical role in
intracellular localization and regulation of proteins in each cell.
This balance is quite important and is typically uncontrolled in
cancer cells. Specific localization of tumor suppressor and oncopro-
teins is quite important because any abnormal localization of these
proteins can cause inactivation or over-activation. Hence it was
believed that inhibitors of nucleocytoplasmic transport systems
could be an anticancer agent for a long time.26 In this respect, con-
centration dependent CRM1 inhibitory properties of klavuzons 3,
16b, 16c, 16d and 20 were studied by visualization of CRM1 medi-
ated nuclear export of Riok2 (Serine/threonine-protein kinase
Rio2) in HeLa cells. CRM1 inhibitory property of goniothalamin
was shown previously and it was used as positive control.17 DAPI
was used to stain the nucleus of the cells for comparison purpose.
For each molecule, number of cells in three separate pictures were
counted and percent inhibition were calculated by dividing the
number of CRM1 inhibited cells to the number of total cells.
According to the results, goniothalamin started to inhibit CRM1
(50%) at 1.0 lM concentration at the end of the 90 min of incuba-
tion and CRM1 was inhibited completely in 100% of the cell popu-
lation at 5 lM concentration. A longer incubation period (6 h) gave
similar trend and at 5 lM concentration, goniothalamin com-
pletely inhibited the nucleocytoplasmic transport system in all
cells (Fig. 6). On the other hand, compound 3 started to inhibit
CRM1 at 0.2 lM concentration even at the end of the 90 min of
incubation (87%). A similar CRM1 inhibition potency was also
found for compounds 16b and 16c. Additionally, compound 16d
could not inhibit CRM1 at 0.2 lM concentration. However, it inhib-
ited CRM1 completely at 1.0 lM concentration at the end of 6 h of
incubation. Interestingly, compounds 16c and 16d had quite simi-
Fig. 6. Time and concentration dependent inhibition of CRM1 in HeLa cells treated with goniothalamin (1), 40-methylklavuzon (3), 40-propylklavuzon (16b), 40-butylklavuzon
(16c), 40-pentylklavuzon (16d) derivatives and compound 20.
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and it is quite difficult to correlate their CRM1 inhibitory potency
with these IC50 values. Lastly compound 20 showed strong CRM1
inhibition activity at 0.2 lM concentration at the end of 6 h of
incubation (Fig. 6). Since compounds 3 and 20 were the most cyto-
toxic klavuzon derivatives, their CRM1 inhibitory properties were
also tested at lower doses (Fig. SM1, Supplementary materials). It
was found that both compounds started to inhibit CRM1 at
20 nM concentrations, and they almost inhibited CRM1 completely
in all cells at 50 nM concentrations.
Lastly, antiproliferative activity of compound 20 was tested
over 3D spheroids generated from HuH-7 hepatocellular cancer
cell line in 96 well hanging drop plates in 48 h. Then varying con-
centrations of compound 20 were applied to the spheroids. Gonio-
thalamin was also applied in a single dose just for comparisonpurpose (Fig. 7). Spheroids were monitored by microscope at the
end of 24, 48, and 72 h of incubation by using 4X objective, then
the same spheroids were treated with propidium iodide (PI) stain-
ing and monitored by fluorescence microscope by using 4X objec-
tive to visualize the dead cells. As it can be seen in Fig. 7, 50 lM
concentration of goniothalamin caused significant cell death just
after 24 h of incubation compared to untreated or DMSO control
HuH-7 spheroids. Although its cytotoxic activity did not increase
in 48 h of incubation, the size of the spheroid was smaller than
the sizes of the untreated or DMSO control spheroids. At the end
of the 72 h of incubation, all of the cells in goniothalamin treated
spheroids were dead.
On the other hand, compound 20 inhibited the growth of 3D
spheroids almost in all tested concentrations and it caused signif-
icant cell death at 10 and 30 lM concentrations in 48 h. Spheroid
Fig. 7. Time and concentration dependent cytotoxic activity of compound 20 in 3D spheroids of HuH-7 cells. Scale bars = 0.5 mm.
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ilar dose dependent response was observed at the end of 72 h of
incubation with compound 20.3. Conclusion
Synthesis of novel 40-alkyl substituted klavuzon derivatives
were successfully completed in eight steps starting from 4-
methyl-1-naphthoic acid. MTT cell viability assay over cancerous
(MIA PaCa-2) and immortalized healthy (HPDEC) pancreatic cell
lines revealed that compound 20 has a remarkable cytotoxic effect
in both cell lines without having any selectivity. Two other novel
klavuzon derivatives, 40-methylklavuzon (3) and 40-ethylklavuzon
(12a), are quite cytotoxic and selective to HPDEC cell line with
IC50 values at nanomolar concentrations. Among these, 40-
methylklavuzon (3) and compound 20were chosen for further bio-
logical activity studies and it is found that 40-methylklavuzon (3)
induces apoptosis in MIA PaCa-2 cells at 5 and 10 lM concentra-
tions. Comet assay also indicates the formation of single and dou-
ble strand DNA breaks in MIA PaCa-2 cells treated with 40-
methylklavuzon (3) for 24 h. Cell cycle analysis of MIA PaCa-2 cells
treated with varying concentrations of compound 3 surprisingly
implies the presence of more than one action of mechanism for this
compound. At 1 lM concentration, compound 3 causes an arrest at
G1 phase while at higher concentrations that results in G2 arrest.
Beside the previously reported Topo I inhibition, time and con-
centration dependent CRM1 inhibitory properties of klavuzon
derivatives have been shown as a second mechanism of action in
this work. Especially, compounds 3 and 20 are the most effective
derivatives and they completely inhibit CRM1 activity at 50 nM
concentrations in 6 h of incubation.
Compared to traditional two-dimensional cell cultures, 3D cell
cultures are considered as a much better way to represent
in vivo environment. Hence, the most active derivative, compound
20, has been tested in HuH-7 derived 3D spheroids and it has been
found that compound 20 inhibited the growth of 3D spheroids andit caused significant cell death at 10 and 30 lM concentrations in
48 h. Therefore, compound 20 can be a good lead compound for
further studies.Author contributions
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